Linezolid Tablet
Product Images NDC 64980-561

19 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Linezolid (NDC 64980-561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Linezolid-tab-2.jpg (Linezolid Tab 2)

Linezolid-tab-2.jpg (Linezolid Tab 2)
A data table comparing adverse reaction rates among patients treated with Linezolid 400 mg every 12 hours, Clarithromycin 250 mg every 12 hours for uncomplicated skin and skin structure infections, and Linezolid 600 mg every 12 hours versus other comparators for all other indications. The table lists side effects such as headache, diarrhea, nausea, vomiting, dizziness, rash, anemia, taste alteration, moniliasis, liver function abnormalities, fungal infection, tongue discoloration, and abdominal pain with corresponding percentage values for each treatment group.*
FDA Label Image

Linezolid-tab-3.jpg (Linezolid Tab 3)

Linezolid-tab-3.jpg (Linezolid Tab 3)
A data table presenting adverse reactions among patients treated for uncomplicated skin and skin structure infections or other indications, comparing Linezolid, Cefadroxil, and Vancomycin. It lists the percentage incidence rates of side effects like diarrhea, vomiting, headache, anemia, thrombocytopenia, nausea, abdominal pain, loose stools, eosinophilia, pruritus, and vertigo across different patient groups.*
FDA Label Image

Linezolid-tab-4.jpg (Linezolid Tab 4)

Linezolid-tab-4.jpg (Linezolid Tab 4)
A data table comparing laboratory assay results for hemoglobin, platelet count, WBC, and neutrophils across treatment groups: Linezolid 400 mg every 12 hours, Clarithromycin 250 mg every 12 hours for uncomplicated skin infections, Linezolid 600 mg every 12 hours for all other indications, and other comparator treatments.*
FDA Label Image

Linezolid-tab-5.jpg (Linezolid Tab 5)

Linezolid-tab-5.jpg (Linezolid Tab 5)
A laboratory assay data table comparing blood test results for liver enzymes, kidney function, and other biomarkers across treatment groups. Columns differentiate between Linezolid 400 mg every 12 hours and Clarithromycin 250 mg every 12 hours for uncomplicated skin infections, and Linezolid 600 mg every 12 hours versus other comparators for all other indications.*
FDA Label Image

Linezolid-tab-6.jpg (Linezolid Tab 6)

Linezolid-tab-6.jpg (Linezolid Tab 6)
A data table comparing laboratory assay values for hemoglobin, platelet count, white blood cell count, and neutrophils between Linezolid and comparator antibiotics Cefadroxil and Vancomycin in the treatment of uncomplicated skin and skin structure infections and all other indications.*
FDA Label Image

Linezolid-tab-7.jpg (Linezolid Tab 7)

Linezolid-tab-7.jpg (Linezolid Tab 7)
A data table comparing laboratory assay values including ALT, Lipase, Amylase, Total bilirubin, and Creatinine levels for Linezolid versus Cefadroxil in uncomplicated skin and skin structure infections, and for Linezolid versus Vancomycin for all other indications.*
FDA Label Image

Linezolid-structure.jpg (Linezolid Structure)

Linezolid-structure.jpg (Linezolid Structure)
Chemical structure of Linezolid, showing its molecular framework including a morpholine ring, fluorophenyl group, and an oxazolidinone core characteristic of the active ingredient.*
FDA Label Image

Linezolid-tab-8.jpg (Linezolid Tab 8)

Linezolid-tab-8.jpg (Linezolid Tab 8)
A pharmacokinetic data table for Linezolid showing parameters for different doses and administration routes including 400 mg tablet, 600 mg tablet, 600 mg IV injection, and 600 mg oral suspension. The table lists Cmax, Cmin, Tmax, AUC, half-life, and clearance values with data for single and multiple doses, including dose normalization and infusion details.*
FDA Label Image

Linezolid-graph.jpg (Linezolid Graph)

Linezolid-graph.jpg (Linezolid Graph)
A line graph showing the plasma concentration of Linezolid over time after a 600 mg oral dose every 12 hours. The x-axis represents time after dose in hours, and the y-axis represents Linezolid plasma concentration in micrograms per milliliter. The graph shows an initial rise, peak, and gradual decline in plasma levels over 12 hours with error bars indicating variability.*
FDA Label Image

Linezolid-tab-9.jpg (Linezolid Tab 9)

Linezolid-tab-9.jpg (Linezolid Tab 9)
A data table presenting pharmacokinetic parameters of Linezolid by age group, including neonatal patients (pre-term and full-term), infant patients, pediatric patients, adolescent subjects, and adult subjects. Parameters shown are maximum concentration (Cmax mcg/mL), volume of distribution (Vss L/kg), area under the curve (AUC mcg•h/mL), half-life (t1/2 hrs), and clearance (CL mL/min/kg), with values including means, variability percentages, and ranges for each group.*
FDA Label Image

Linezolid-tab-10.jpg (Linezolid Tab 10)

Linezolid-tab-10.jpg (Linezolid Tab 10)
A data table comparing pharmacokinetic parameters of Linezolid and its metabolites A and B in healthy subjects versus patients with moderate and severe renal impairment. Parameters include AUC (mcg h/mL) and half-life (t1/2 in hours), highlighting increased metabolite levels and half-life with worsening renal function.*
FDA Label Image

Linezolid-tab-11.jpg (Linezolid Tab 11)

Linezolid-tab-11.jpg (Linezolid Tab 11)
A data table showing pharmacokinetic parameters for Linezolid and its metabolites A and B in ESRD subjects. It lists AUC (mcg h/mL) and half-life (t1/2, hours) after the last dose for each, including notes that Metabolite B is the major metabolite and measurements are taken between hemodialysis sessions.*
FDA Label Image

Linezolid-tab-12.jpg (Linezolid Tab 12)

Linezolid-tab-12.jpg (Linezolid Tab 12)
A table comparing the cure rates of different pathogens treated with Linezolid versus Vancomycin. It includes data for Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus pneumoniae, showing the number and percentage of cases cured by each treatment.*
FDA Label Image

Linezolid-tab-13.jpg (Linezolid Tab 13)

Linezolid-tab-13.jpg (Linezolid Tab 13)
A data table comparing cure rates of pathogens treated with Linezolid versus Oxacillin/Dicloxacillin. It lists cure percentages for Staphylococcus aureus, Methicillin-resistant S. aureus, Streptococcus agalactiae, and Streptococcus pyogenes with respective cure rates shown as counts and percentages for both treatments.*
FDA Label Image

Linezolid-tab-14.jpg (Linezolid Tab 14)

Linezolid-tab-14.jpg (Linezolid Tab 14)
A data table showing the cure rates of different pathogens comparing Linezolid to a comparator. The pathogens listed are Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus agalactiae, with cure percentages for each under Linezolid and the comparator treatments.*
FDA Label Image

Linezolid-tab-15.jpg (Linezolid Tab 15)

Linezolid-tab-15.jpg (Linezolid Tab 15)
Data table presenting cure rates of infections at various sites treated with Linezolid 600 mg or 200 mg every 12 hours. The table compares number and percentage cured by infection source including skin, urinary tract, pneumonia, and others, showing higher cure rates for the 600 mg dose across most categories.*
FDA Label Image

Linezolid-tab-16.jpg (Linezolid Tab 16)

Linezolid-tab-16.jpg (Linezolid Tab 16)
A data table comparing clinical outcomes for Linezolid and Vancomycin across different patient populations. It includes counts and percentages for ITT, MITT, and Clinically Evaluable groups with diagnoses such as any diagnosis, complicated skin and skin structure infections, and nosocomial pneumonia. MITT refers to patients with an isolated Gram-positive pathogen at baseline.*
FDA Label Image

Linezolid-tab-17.jpg (Linezolid Tab 17)

Linezolid-tab-17.jpg (Linezolid Tab 17)
A table comparing microbiological evaluability of Linezolid and Vancomycin against pathogens including Vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus pyogenes, showing numbers and percentages of effectiveness for each drug. The table notes data from an open-label extension study with 7 patients.*
FDA Label Image

Linezolid-label.jpg (Linezolid Label)

Linezolid-label.jpg (Linezolid Label)
Linezolid Tablets USP 600 mg oral tablets packaging label from Rising Pharmaceuticals. The label shows the product name, strength, quantity of 20 tablets, and indicates prescription use only (Rx only). It includes storage instructions, manufacturer information, NDC 64980-561, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.